The Shifting Sands of the GLP-1 Market: Why Eli Lilly is Surging Ahead For years, Novo Nordisk’s Ozempic and Wegovy dominated conversations around GLP-1 drugs – a class of medications initially designed for type 2 diabetes, but quickly gaining traction for weight loss. However, the landscape is changing. While Novo Nordisk was the first to … Read more
Wegovy’s Higher Dose Approved in EU: A Game Changer for Obesity Treatment? The European Commission has granted approval for a higher dose of Novo Nordisk’s Wegovy (semaglutide), offering a potentially more effective option for adults struggling with obesity. This decision, finalized on February 17, 2026, extends the availability of the 7.2mg weekly injection to all … Read more
Novo Nordisk’s Next Act: Can CagriSema Reclaim GLP-1 Dominance? Ozempic has been a major growth driver for Novo Nordisk (NYSE: NVO) for years, becoming a household name in the process. However, the Danish drugmaker has recently lost ground to Eli Lilly (NYSE: LLY) in the competitive GLP-1 market. Can Novo Nordisk regain its footing? The … Read more
The Future of Hypertension Treatment: Could Injections Replace Pills? For decades, managing high blood pressure has meant a lifetime of daily medication. But a significant shift is on the horizon. Fresh long-acting injectable therapies are in late-stage clinical trials, offering the potential to control blood pressure with just two injections per year. This could revolutionize … Read more
The Shifting Sands of the Weight-Loss Market: Opportunities Beyond the GLP-1 Hype Even as Eli Lilly (NYSE: LLY) currently dominates investor attention with its blockbuster GLP-1 drugs, Mounjaro and Zepbound, a closer look reveals potential opportunities in the stocks of its competitors, Novo Nordisk (NYSE: NVO) and Pfizer (NYSE: PFE). The market isn’t a one-horse … Read more
The Rise of Compounded Wegovy: A Glimpse into the Future of Weight Loss & Pharma The recent move by Hims & Hers to offer a compounded version of Wegovy, Novo Nordisk’s blockbuster weight loss drug, isn’t just a business decision – it’s a potential earthquake in the pharmaceutical landscape. Novo Nordisk’s swift accusation of “illegal … Read more
The $49 Wegovy Pill: A Crack in Big Pharma’s Pricing Fortress? The pharmaceutical landscape shifted dramatically this week as telehealth company Hims and Hers Health launched a compounded version of Novo Nordisk’s Wegovy weight-loss pill for just $49 a month. This aggressive pricing, significantly undercutting Novo Nordisk’s $149 list price and anticipated competition from Eli … Read more
Novo Nordisk’s CagriSema: A New Era in Weight Loss and Diabetes Treatment? Novo Nordisk’s recent Phase 3 data for CagriSema is sending ripples through the pharmaceutical industry. The combination drug, pairing semaglutide with the novel amylin receptor agonist cagrilintide, demonstrably outperformed Wegovy in clinical trials, offering a potentially significant leap forward in the treatment of … Read more
The Pill is the New Shot: How Sam Chun Dang is Pioneering Oral Weight Loss & Beyond The race to deliver weight-loss medications in pill form is heating up, and South Korea’s Sam Chun Dang Pharm (SCD) is rapidly emerging as a frontrunner. A recent surge in the company’s stock – up over 75% this … Read more
Ozempic’s Reinvention: How Novo Nordisk is Fighting to Keep its GLP-1 Crown Novo Nordisk, once the undisputed leader in the GLP-1 receptor agonist market with its blockbuster drug Ozempic, is facing a rapidly changing landscape. A prolonged shortage, coupled with the rise of formidable competitors like Eli Lilly’s Mounjaro, has forced the Danish pharmaceutical giant … Read more